Flibanserin, marketed under the brand name Addyi, is the only FDA-approved medication specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. It’s important to understand that Addyi doesn’t work like Viagra for men. It doesn’t directly increase blood flow. Instead, it affects brain neurotransmitters to potentially improve sexual desire.
Addyi’s mechanism involves increasing serotonin and decreasing dopamine and norepinephrine levels in the brain. This altered neurotransmitter balance aims to improve sexual desire, though its effectiveness varies significantly among individuals.
Before considering Addyi, consult your doctor. They will assess your medical history, rule out other underlying medical conditions contributing to HSDD, and discuss potential side effects. These can include nausea, dizziness, sleepiness, and low blood pressure. Alcohol consumption is strictly prohibited while taking Addyi due to increased risk of low blood pressure.
Clinical trials showed a modest improvement in sexual desire for some women taking Addyi. However, many women did not experience significant benefit. The results suggest that Addyi might be a viable option for a subset of women with HSDD, but it is not a guaranteed solution for all.
Discuss alternative treatments with your doctor if Addyi proves ineffective or causes unacceptable side effects. These could include counseling, therapy, or other approaches addressing the underlying causes of HSDD. Remember, open communication with your healthcare provider is vital for finding the best approach to manage your individual needs.
Always follow your doctor’s instructions carefully and report any adverse reactions immediately. Self-medicating with Addyi or any other medication is strongly discouraged. Proper medical supervision is critical for safe and effective treatment.
